Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback